Menu Search
Equities

Faron Pharmaceuticals Oy

FPHAF:PKC

Faron Pharmaceuticals Oy

Actions
  • Price (USD)3.30
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Feb 11 2022.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Faron Pharmaceuticals Oy's net income fell 35.46% from a loss of 21.21m to a larger loss of 28.73m despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-234.98%
Return on equity--
Return on investment-844.50%
More ▼

Cash flow in EURView more

In 2022, Faron Pharmaceuticals Oy did not generate a significant amount of cash. Cash Flow from Financing totalled 23.48m or -- of revenues. In addition the company used 22.99m for operations while cash used for investing totalled 385.00k.
Cash flow per share-0.4472
Price/Cash flow per share--
Book value per share-0.1667
Tangible book value per share-0.1835
More ▼

Balance sheet in EURView more

Faron Pharmaceuticals Oy appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money. Faron Pharmaceuticals Oy has considerable financial risk.
Current ratio0.9292
Quick ratio--
Total debt/total equity--
Total debt/total capital7.40
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.